Longeveron Inc., abbreviated as LGVN on the stock market, is a clinical-stage biotechnology company that specializes in the development of cell therapies for aging-related and life-threatening conditions. The Miami, Florida-based company was established in 2014 and has been at the forefront of clinical trials targeting the biology of aging.

Longeveron's main product is Lomecel-B, a stem cell treatment which is being explored in clinical trials for diseases such as Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, and hypoplastic left heart syndrome. Aging Frailty is a common geriatric medical condition characterized by a loss of physiological reserves, thereby increasing a person's vulnerability to sudden health status changes.

Longeveron Inc. is rigorously committed to revolutions in the therapeutic approach to aging-related diseases. Their work revolves around mesenchymal stem cells (MSCs), which are derived from the bone marrow of young, healthy adult donors. These MSCs have anti-inflammatory and immunomodulatory properties and can potentially replace or repair damaged tissues, which makes them exceptional candidates for cell therapy.

What makes Longeveron’s work unique and promising is their use of allogeneic cells, which means the cells are obtained from a donor, not the patient. These cells can be expanded in culture to create a large number of dose units from a single donation, stored for future use, and made readily available for "off-the-shelf" use, making the process more efficient and accessible.

Longeveron Inc. strives to break new ground in the field of regenerative medicine. They have collaborations with prominent academic research institutions in the field of cell-based therapies and regulatory bodies globally.

At Longeveron, breakthroughs in science are set to make aging better and more sophisticated. The company aims to harness the power of the human body itself to stimulate natural healing abilities, creating therapies that have far-reaching implications for both the quality of life and longevity.

The company’s shares have been publicly traded on NASDAQ since February 2021 under the stock symbol LGVN, opening an opportunity for investors interested in supporting innovative solutions to complex medical challenges. With its scientific caliber and commitment to life-improving therapies, Longeveron stands as a bold leader in the biotech industry.